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Erythrocyte encapsulated thymidine phosphorylase is recombi-
nant Escherichia coli thymidine phosphorylase encapsulated
within human autologous erythrocytes and is under develop-
ment as an enzyme replacement therapy for the ultra-rare
inherited metabolic disorder mitochondrial neurogastrointes-
tinal encephalomyopathy. This study describes the method
validation of a two-step bridging electrochemiluminescence
immunoassay for the detection of anti-thymidine phosphory-
lase antibodies in human serum according to current industry
practice and regulatory guidelines. The analytical method was
assessed for screening cut point, specificity, selectivity, preci-
sion, prozone effect, drug tolerance, and stability. Key findings
were a correction factor of 129 relative light units for the cut-
point determination; a specificity cut point of 93% inhibition;
confirmed intra-assay and inter-assay precision; assay sensi-
tivity of 356 ng/mL; no matrix or prozone effects up to
25,900 ng/mL; a drug tolerance of 156 ng/mL; and stability at
room temperature for 24 hr and up to five freeze-thaws. Immu-
nogenicity evaluations of serum from three patients who
received erythrocyte encapsulated thymidine phosphorylase
under a compassionate treatment program showed specific
anti-thymidine phosphorylase antibodies in one patient. To
conclude, a sensitive, specific, and selective immunoassay
has been validated for the measurement of anti-thymidine
phosphorylase antibodies; this will be utilized in a phase II
pivotal clinical trial of erythrocyte encapsulated thymidine
phosphorylase.
INTRODUCTION
Enzyme replacement therapies are typically applied to the treatment
of individuals with inherited enzyme deficiency disorders, whereby
the deficient enzyme is replaced by regular infusions of the normal
counterpart, with the aim of decelerating the disease progression
process. Current licensed preparations are either purified from natu-
ral human or animal sources, or produced by recombinant technolo-
gies, and thus have the potential to induce undesirable immune
responses. Clinical experience has shown that the development of
anti-enzyme antibodies is a common occurrence, with many of the
approved enzyme replacement therapies exhibiting immunogenicity
rates of 51%–100%.1,2 Clinical complications of immunogenic reac-
tions include the modification of therapeutic efficacy and acute infu-
sion reactions, such as anaphylaxis. Appropriately, the appraisal of
anti-enzyme antibody formation is a crucial component of the clinical
development program and is specifically relevant during the evalu-
ation of the enzyme’s efficacy and safety profile. There is thus a reg-
ulatory expectation that a valid, sensitive, specific, and selective
immunoassay is developed for measuring enzyme-specific antibody
responses.3,4
Erythrocyte encapsulated thymidine phosphorylase (EETP) is under
development as an enzyme replacement therapy for the rare
metabolic disorder mitochondrial neurogastrointestinal encephalo-
myopathy, abbreviated to MNGIE.5–7 The disease is caused by
mutations in the nuclear TYMP gene encoding for the enzyme
thymidine phosphorylase (TP), leading to elevated concentrations
of thymidine and deoxyuridine in cellular and extra-cellular com-
partments, and ultimately mitochondrial failure due to progressive
accumulation of mtDNA defects and mtDNA depletion.8–12 Clini-
cally, MNGIE manifests as leukoencephalopathy, ptosis and
ophthalmoplegia, peripheral polyneuropathy, and enteric neuromy-
opathy, causing severe gastrointestinal dysmotility with cachexia.13
The disorder invariably leads to death at an average age of
37.6 years.
EETP is produced by encapsulating recombinant Escherichia coli
(E. coli) TP within autologous erythrocytes ex vitro; the loaded cells
are then infused into the patient. The rationale for this approach is
based on thymidine and deoxyuridine diffusing across the erythro-
cyte membrane via nucleoside transporters into the cell where the
encapsulated enzyme catalyzes their metabolism to the normal
products. The administration of EETP under a compassionate treat-
ment program has shown a sustained reduction or elimination of
plasma thymidine and deoxyuridine concentrations, translating
into clinical improvement.5,6,14,15 EETP therapy has the advantage
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of prolonging the circulatory half-life of the enzyme and potentially
minimizing the immunogenic reactions, which are frequently
observed in enzyme replacement therapies administered by the con-
ventional route.
We describe here the validation of a two-step immunoassay method
for the detection of anti-TP antibodies in human serum for support-
ing a phase II pivotal clinical trial of EETP. The analytical method was
assessed for screening cut point, specificity, intra-assay and inter-
assay precision, sensitivity, selectivity, drug tolerance, prozone effect,
and stability.
RESULTS
The key results from this validation study are presented in Table 1.
Disease State Matrix
Of the seven disease matrix samples from untreated patients that were
screened, five were negative for anti-TP antibodies. The difference in
the mean instrument responses between the patient and normal
matrix samples was 10.1%; this was not considered to be significant
(see Table S1), indicating that the same cut point can be applied
(see below).
Screening and Specificity Cut Point
The signal distribution for the 51 negative control (NC) samples was
normally distributed (p>0.05)withnooutliers. Thevalidation cut point
was calculated to be 898.5 relative light units (RLUs) (see Table 2,
first iteration).
Statistically significant differences were evident between the means
for analyst, day, plate, analyst by plate, analyst by day, and analyst
by day by plate interactions (p < 0.001) and also the variances
(p < 0.001) indicating a dynamic screening cut point (see Figure S1).
Each analyst was analyzed separately to determine the source of
these differences. For analyst 1, there were significant differences be-
tween the means for day, plate, and their interaction, but not the
variances, indicating a floating screening cut point. For analyst 2,
there were significant differences between the means for day, plate,
and their interaction and the variances, indicating a dynamic cut
point. Due to practical limitations of using a dynamic cut point,
the validation study continued using analyst 1, thereby applying a
floating cut point that was calculated as 1,066.6 RLUs (see Table 2,
second iteration). The correction factor for the screening cut point
for analyst 1 was estimated to be 128.6 RLUs, and this was applied
to subsequent assays.
An analysis of the specificity cut-point data revealed a normal distri-
bution and one outlier, which was excluded. The fixed specificity cut
point was calculated to be 93% inhibition (Figure 1). Statistically sig-
nificant differences were evident between the means for analyst, day,
plate, analyst by day, day by plate, and analyst by day by plate inter-
actions (p < 0.001).
Sensitivity
Assay sensitivity analysis was determined from data generated by
analyst 1 only and was calculated as 356 ng/mL (see Table S2).
Controls
The NC samples were below the cut point, the LPC samples above the
cut point, and the high positive control (HPC) samples at the high end
of the dynamic range for both intra-assay and inter-assay analyses,
Table 1. Summary of Key Validation Parameters for the Assessment of Anti-
TP Antibodies in Human Serum
Validation Parameter Results
Positive control standard range 2.44–10,000 ng/mL
Correction factor for cut-point calculation 129 RLUs
Screening cut point floating cut point
Specificity cut point 93.0%
Assay sensitivity 356 ng/mL
Intra-assay Performance Precision, CV (%)
Negative control 14.5
Low positive control 11.1
High positive control 1.0
Inter-assay Performance Mean Precision, CV (%)
Negative control 43.3
Low positive control 40.6
High positive control 30.5
Assay drift not present
Minimum required dilution (MRD) 1 in 10
Selectivity (matrix effects) not present
Prozone not present up to 25,900 ng/mL
Drug tolerance tolerant up to 156 ng/mL
Confirmatory drug concentration 12,500 ng/mL
Stability
Room temperature up to 24 hr
Freeze-thaw up to five freeze-thaw cycles
RLU, relative light unit.
Table 2. Screening Cut-Point Determination
Parameter RLUs




Cut point 898.5 1,066.6
Mean of negative controls 814.2 938
Correction factor – 128.6
The cut point was determined using 51 individual lots of serum, analyzed in duplicate,
by 2 analysts, over 3 plates, on 3 days. The cut point was calculated as the RLUs +
1.645*SD. The first iteration represents data analyzed from analysts 1 and 2. Data
from analyst 2 were removed for the second iteration.
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and are therefore considered suitable. Controls pre-incubated in the
presence of 12,500 ng/mL TP demonstrated RLUs below the cut point
in both intra-assay and inter-assay analyses, with inhibitions ranging
between 80.6% and 98.8% (Table 3).
Assay drift was not observed, as indicated by a mean difference in
response readings of the control samples at the beginning and end
of the assay plate being within ±30%, when compared with each other
(data not shown).
Drug Tolerance
The drug tolerance of the analytical method was determined at
156 ng/mL (Figure 2).
Selectivity
All low and high spiked samples were above the cut point without TP
and below the cut point with TP. Inhibitions at the confirmatory drug
concentration (12,500 ng/mL) were observed for the high spiked
patient and control samples (Figure 3). Matrix effects with regard
to the therapeutic enzyme and disease state matrix are therefore not
considered significant.
Prozone
The instrument response readings remained above the assay cut
point; therefore, prozone effects were not observed up to a serum
anti-TP antibody concentration of 25,900 ng/mL, 2.59-fold higher
than the HPC (data not shown).
Stability
Anti-TP antibodies were stable up to 24 hr at room temperature and
for up to five cycles of freeze-thaw at 70C (Figure 4). The preci-
sion (% coefficient of variation [CV]) of the instrument responses
was %20%.
Evaluation of Serum Samples from Treated Patients
Serum samples from three patients were analyzed before treatment
and at different time points during treatment (Table 4). The mean
instrument responses for all pre-treatment samples were below the
assay cut point. For patient 1, one sample after 9 months of treatment
was above the cut point. For patient 2, all samples during the treat-
ment phase were above the cut point. For patient 3, one sample after
5 months of treatment was above the cut point. All positive samples
from patient 2 were found to be specific in the confirmatory assay.
Positive samples for patients 1 and 3 were confirmed as non-specific
antibodies because the inhibition was below the specificity point
of 93%.
DISCUSSION
Autologous erythrocyte-mediated enzyme replacement is employed
as a strategy for preventing or minimizing the development of
immune reactions against therapeutic enzymes. Our experience in-
cludes the treatment of a patient with adenosine deaminase deficiency
with erythrocyte encapsulated adenosine deaminase and the admin-
istration of EETP to five patients withMNGIE under a compassionate
use program.5,6,14–17 A recombinant E. coli source of GMP TP has
been developed to support a clinical trial of EETP. Although erythro-
cyte encapsulation would be predicted to reduce the immunogenicity
of the enzyme, an intravascular release of TP from damaged erythro-
cytes is likely to evoke an immunogenic reaction against a protein of
bacterial origin. The evaluation of the immunogenicity of therapeutic
enzymes is an important aspect of clinical development because the
formation of anti-enzyme antibodies can negatively influence the
efficacy and safety of the proposed treatment.
In this study, we validated a method for the detection of anti-TP
antibodies in the serum of patients treated with EETP according to
published recommendations for the design and optimization of
immunoassays for the detection of host antibodies against therapeutic
proteins.3,4,18–21 To minimize the false-positive rate and to increase
specificity, we adopted a two-step analysis: a screening assay for the
identification of anti-TP-positive patient samples, followed by an
assay for confirming the presence of anti-TP antibodies. Due to hav-
ing the potential to detect all antibody isotypes and classes produced
in an immune response, an electrochemiluminescent bridging immu-
noassay platform was selected. Fifty-one individual control serum
samples were used to determine the 95% confidence interval used
as the cut-point factor. The cut-point factor was added to the mean
signal for the pooled NC serum on each plate to establish the cut
point. In the second analysis step, a confirmation assay was developed
to confirm the specificity of putatively positive samples identified in
the screening assay. In this approach, PC samples were pre-incubated
with and without a high concentration of TP to inhibit the assay signal
Figure 1. Specificity Cut Point
To establish the specificity cut point, we pre-incubated 51 individual control serum
samples with TP at a concentration of 12,500 ng/mL and analyzed them in
duplicate by two analysts over three plates on 3 days to assess % signal inhibition.
Significant differences were observed between the means for analyst, day, plate,
analyst  day, day  plate, and analyst  day  plate interactions (p < 0.001).
Data are expressed as mean % signal inhibition ± SD.
www.moleculartherapy.org
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beyond the cut-point value; inhibition above the cut point confirmed
the presence of anti-TP antibodies. Ideally, cut-point assessments
should be conducted using disease state serum samples; however,
for rare diseases, obtaining a sufficient number of patient samples is
challenging. To address possible differences between control and
diseases matrices, assay selectivity testing was assessed in patient
and NCmatrix samples. The bioanalytical guidelines of the European
Medicines Agency (EMA) and US Food and Drug Administration
(FDA) recommend the testing of at least 10 individual sources of sam-
ple matrix; however, because of the rarity of MNGIE, only seven
patient matrix samples were available for testing.22,23 The mean
instrument responses between the patient and NC matrix samples
nevertheless were not significantly different, therefore demonstrating
the absence of disease matrix effects. Testing a larger number of sam-
ples will be contemplated during the clinical trial when more patients
will be available.
The assay provided an adequate sensitivity of 356 ng/mL of polyclonal
antibodies in serum; this is in the accepted range of 250–500 ng/mL in
serum for antibody assays in clinical trials.24 Drug tolerance was
156 ng/mL; in patient compassionate use studies, plasma levels of
free TP are undetectable, and therefore assay interference by free
TP is considered negligible.
No specific anti-TP antibodies were detected in patients 1 and 3,
determined using the confirmatory assay. However, in patient 2,
positive anti-TP antibodies were detected after 8 months of treatment
(after nine administrations of EETP) onward. The development of
anti-TP antibodies does not necessarily predict the development of
adverse events in patients, but could potentially impact on the efficacy
of TP by inhibiting the pharmacological activity of the enzyme
through the formation of immune complexes. Another clinical conse-
quence of antibody formation is cross-reactivity with an endogenous
protein, which performs a key physiological function. The develop-
ment of specific anti-TP antibodies in patient 2 did not raise any spe-
cific concerns with regard to the efficacy of encapsulated TP, because
depletion of the plasma metabolites improved over the 5.5 years of
administration, and clinical improvements were also recorded.15
Nevertheless, heterogeneity in patient antibody responses are often
observed, and thus sufficient data should be compiled during clinical
development to characterize antibody response variability. Guidelines
of the FDA and EMA recommend that specific antibody responses are
further analyzed for neutralizing capacity.3,4,25 Neutralizing antibody
assay validation was not included in this study, and although we
anticipate that it is unlikely that neutralizing antibodies will be
formed due to the encapsulation of TP in the erythrocyte, a relevant
assay will be validated during clinical development and prior to mar-
keting authorization applications. Pre-clinical studies with EETP
demonstrated specific anti-TP antibodies in 2 of 18 treated dogs
and 19 of 60 treated BALB/c mice.7 The development of specific an-
tibodies against TP is not a surprising observation because senescent
erythrocytes are naturally sequestered from the vascular compart-
ment by macrophages of the monocyte-macrophage system, which
is able to present antigens to T lymphocytes. We have previously
shown that humoral responses can be elicited by the administration
of erythrocyte encapsulated antigens to BALB/c mice.26 One of the
advantages of employing the autologous erythrocyte is that the devel-
opment of antibodies against the carrier is unlikely, and indeed this
has not been encountered in 25 years of clinical experience.
To conclude, this assay has appropriate performance characteristics
and is considered suitable for the detection of anti-TP antibodies in
human serum. Further assay refinement will be implemented during
clinical development to include the validation of a neutralizing anti-
body assay and detection of IgE antibodies.
MATERIALS AND METHODS
This validation study was designed to adhere to recommendations for
the validation of immunoassays used for detection of host antibodies
against biotechnology products according to FDA and EMA immu-
nogenicity guidelines and in compliance with Good Laboratory Prac-
tice (GLP) standards.3,4,18–21,24
Reagents
All reagents were supplied by Meso Scale Discovery, UK, unless
otherwise stated. The wash buffer was PBS with 0.05% Tween 20
(Sigma Chemical Company, UK). Blocker A solution consisted of
5% (w/v) blocker A in phosphate buffer; the assay buffer was 1 vol
of 5% blocker A solution and 4 vol of wash buffer, and the Read buffer
(4) was diluted 1:2 with ultra-high-purity-grade water.
Table 3. Intra-assay and Inter-assay Analysis of Control Samples with and without Pre-incubation with TP
Control Sample Intra-assay Inter-assay
RLUs (Mean ± SD) CV (%) % Inhibition RLUs (Mean ± SD) CV (%) % Inhibition
NC 865 ± 126 14.5 – 483 ± 209 43.3 –
NC+TP ND ND ND 87 ± 10 11.0 80.6
LPC 1,505 ± 167 11.1 – 919 ± 373 40.6 –
LPC+TP 151 ± 8 5.3 90.0 103 ± 27 25.8 88.9
HPC 18,111 ± 181 1.0 – 12,680 ± 3,873 30.5 –
HPC+TP 265 ± 3 1.0 98.5 158 ± 59 37.4 98.8
ND, not determined; TP, thymidine phosphorylase.
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Recombinant E. coli (TP, 13 mg/mL) produced by the methodology
employed for the manufacture of clinical GMP material was em-
ployed for the development and validation of this immunoassay
(Diatheva, Italy). A 12,500-ng/mL working solution of TP was
prepared by dilution in assay buffer. Biotinylated and sulfo-TAG
TP conjugates were prepared as the capture and detection anti-
gens, respectively, as described previously and were used to formu-
late a conjugate mastermix complex working solution containing
300 ng/mL biotin and 300 ng/mL sulfo-TAG in assay buffer.27
Negative and Positive Human Serum Controls
An NC human serum pool was prepared from 15 individual human
samples that had been screened against a positive control calibration
curve for the presence of anti-TP antibodies and stored at 20C
until required. Positive human serum controls (PC) were prepared
from affinity-purified rabbit anti-TP antibody (0.518 mg/mL; custom
produced by Open Biosystems, Huntsville, AL, USA) diluted with NC
sera to produce the low PC just above the cut point (low positive con-
trol [LPC], 400 ng/mL) and a high PC giving approximately 75% of
the maximum signal (HPC, 10,000 ng/mL). Prior to analysis, the
NC and PC samples were diluted 1:10 with assay buffer.
Samples from Patients with MNGIE
To ascertain that the normal matrix was representative of the disease
state matrix, we screened and analyzed 7 individual treatment-naive
disease state human serum samples alongside 10 individual NC
samples.
Serum samples from three patients with a confirmed diagnosis of
MNGIE who had received two to four weekly infusions of EETP
(3.9–108 U/kg body weight) were collected pre-treatment and at a
number of time points after therapy initiation. Samples were stored
at 80C in a temperature-monitored freezer until sample analysis,
by a two-tiered process, consisting of a screening assay to identify
samples positive for anti-TP antibodies, followed by a confirmatory
assay to establish whether the antibodies were specific to TP. NC,
LPC, and HPC samples were included in each assay run. Approval
for the study was obtained from the National Research Ethics Service
Committee. Patient informed consent was obtained prior to the start
of treatment.
Assay Procedure
Assays were performed using an electrochemiluminescent bridging
immunoassay. In brief, NC, PCs, and test samples were diluted in
assay buffer with and without TP for 1 hr at room temperature, after
which 75 mL was added to wells of a polypropylene 96-well plate
(Fisher Scientific, UK) followed by 75 mL of conjugate mastermix.
The plates were covered and incubated at room temperature for
2 hr with shaking at 800 rpm. Following this, 350 mL of blocker
A solution was added to the appropriate wells of a streptavidin gold
plate, which was then covered and incubated at room temperature
for 2 hr with shaking at 800 rpm. The streptavidin plate was then
washed three times with 350 mL of wash buffer per well using a plate
washer; the last wash was aspirated and the plate blotted dry by inver-
sion over absorbent paper. Two 50-mL aliquots from each well of the
polypropylene 96-well plate were transferred to corresponding dupli-
cate wells in the streptavidin plate, which was then covered and incu-
bated at room temperature for 1 hr, with shaking at 800 rpm. This was
followed by three washes with 350 mL of wash buffer per well using a
plate washer; the last wash was aspirated and the plate blotted dry by
inversion over absorbent paper. Finally, 150 mL of Read buffer (2)
Figure 3. Assay Selectivity
Individual control (n = 10) and disease (n = 7) serum samples were unspiked or
spiked with anti-TP antibodies at low (400 ng/mL) and high (10,000 ng/mL) con-
centrations. Two aliquots of each sample were prepared and incubated for 1 hr, one
aliquot with buffer and the other aliquot with free TP (12,500 ng/mL). Dotted line
represents assay cut point. Data are expressed as log mean RLUs ± SD.
Figure 2. Assay Tolerance to Free TP
Instrument response as function of TP concentration. The LPC was spiked with TP
over a concentration range of 39.1–40,000 ng/mL and incubated for 1 hr before
analysis. The blue arrow indicates the assay drug tolerance.
www.moleculartherapy.org
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Design Expert was used to optimize the concentrations of biotinylated
TP and sulfo-TAG TP.
PC Standard Curve for Assay Sensitivity Determination
PC calibration curves were prepared from working standards (n = 2,
in duplicate) and processed using a four-parameter logistical algo-
rithm; this fitting routine was applied throughout the determination
of screening and specificity cut point and assay sensitivity.
Screening and Specificity Cut Point
The screening cut point was assessed to determine the threshold for
identifying samples as negative or potentially positive (equal or above
the cut point) for the presence of anti-TP antibodies. The methodol-
ogy applied was that of Shankar et al.,18 where the purpose was to
determine the type of cut point required (floating, fixed, or dynamic),
calculate the cut-point value, and determine the specificity (confirma-
tion) cut point. Fifty-one individual human serum samples were
measured in duplicate, by two analysts, over three plates, on 3 days.
The specificity cut point assay is employed to determine whether sam-
ples identified as potentially reactive in the screening assay are posi-
tive or negative for anti-TP antibodies. The same source of serum
samples that were employed in the screening cut-point assay were
pre-incubated with TP at a concentration of 12,500 ng/mL, this being
10 times the lowest concentration that was observed to fall below the
screening cut point during assay development. Each assay run
included a PC standard curve, NC, LPC, and HPC samples, with
and without TP.
Assay Sensitivity
The sensitivity of the assay is defined by the lowest concentration at
which a PC antibody preparation consistently provides a positive
signal in the assay. This was calculated as the mean concentration ob-
tained by interpolation of the plate-specific cut-point value against
the PC curve on each of the 18 assay runs described above and
then determining the lowest concentration that is measured as posi-
tive 95% of the time. Instrument responses, RLUs for the PC samples,
were assessed according to their relation to the cut point.
PC and NC Sample Suitability
Intra-assay precision was determined by the replicate analysis of NC
(four independent preparations of NC, three independent prepara-
tions of LPC, and three independent preparations of the HPC samples
in one assay run). An additional set of control samples pre-incubated
with 12,500 ng/mL TP was also analyzed. Inter-assay precision was
determined from the replicate analysis of 4 independent preparations
of NC, 2 independent preparations of LPC, and 2 independent prep-
arations of HPC samples, with and without TP on 15 occasions span-
ning 4 different days, by 2 analysts. Assay drift was assessed by
analyzing control samples (+ pre-incubation with TP) in the first
and last columns of the assay plate.
Drug Tolerance
The tolerance of the assay to free TP was assessed by pre-incubation
of the LPC for 1 hr in TP over the final concentration range of 39.1–
40,000 ng/mL. A sample without TP was also analyzed.
Table 4. Screening Analysis and Confirmatory Assay of Positive Patient
Samples





pre-treatment negative – –
9 positive 73.7 non-specific
15 negative – –
21 negative – –
28 negative – –
2
pre-treatment negative – –
8 positive 95.5 specific
16 positive 98.8 specific
22 positive 97.3 specific
28 positive 98.1 specific
35 positive 98.5 specific
41 positive 98.8 specific
49 positive 99.1 specific
60 positive 99.0 specific
73 positive 97.6 specific
3
pre-treatment negative –
6 positive 75.6 non-specific
TP, thymidine phosphorylase.
Figure 4. Stability of Anti-TP Antibody after 24 hr at Room Temperature and
after Repeated Freeze-Thaw Cycles
The dashed lines represent the assay cut-point range. Data are expressed as log
mean RLUs ± SD.
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Selectivity
Assay selectivity was assessed to determine whether the assay was
affected by the disease state matrix or by the potential existence of
therapeutic TP in serum samples. Individual control (n = 10) and dis-
ease (n = 7) serum samples were unspiked and spiked with anti-TP
antibodies at low (400 ng/mL) and high (10,000 ng/mL) concentra-
tions. Two aliquots of sample were prepared and incubated for
1 hr, one aliquot with buffer and the other aliquot with assay buffer
containing free TP (12,500 ng/mL). The samples were distributed
over four assay runs. The percentage inhibition of signal in the pres-
ence of free TP was calculated using the formula described in Data
Handling and Statistics.
Prozone
Assay prozone caused by high anti-TP antibody levels was investi-
gated by serial dilution of a high spiked sample (containing anti-TP
antibodies at a concentration of 25,900 ng/mL) with assay buffer.
Stability
The effect of anticipated sample handling conditions on assay per-
formance was evaluated, specifically bench top storage at room tem-
perature (nominally 22C) and repeated freeze-thaw cycles. Room
temperature effects were assessed by thawing one set of PC samples
for approximately 24 hr (expected maximum duration that samples
would be left thawed) and an additional set for baseline assessment,
just prior to analysis (n = 3, in duplicate). The effect of repeated
freeze-thaw cycles on the stability of anti-TP antibodies was as-
sessed by subjecting PC samples to three and five freeze-thaw cycles,
with each cycle consisting of a minimum of 2 hr at room temper-
ature, followed by storage at 70C for at least 12 hr (n = 3, in
duplicate). An additional set of PC samples for baseline assessment
was thawed prior to analysis. Stability was verified if the mean pre-
cision (% CV) and mean percent difference from the baseline
responses were %20%.
Data Handling and Statistics
Instrument responses are reported as mean values of RLU. All data
acquisition, processing, and evaluations were performed using the
Watson Laboratory Information Management System version 7.2,
Microsoft Excel, and Meso Scale Discovery Workbench version
3.0.185. Data for cut-point calculation were analyzed using SAS
Version 9.1.3.
Assay cut-point evaluation was performed using the statistical meth-
odology described by Shankar et al.18 Measurements for each of the
51 human serum samples (n = 18, in duplicate) were averaged and
tested for normality using the Shapiro-Wilk’s test;28 logarithmic
(base 10) or square root transformation was applied to non-normally
distributed data. An assessment for outliers was made using the Stu-
dentized Deleted Residuals whereby residues <3 or >3 SDs were
excluded. Once outliers were removed, data were reassessed for
normality; the validation cut point was defined as the 95% quantile
for non-normally distributed data, or the mean + 1.645*SD for nor-
mally distributed data.
To assess the type of screening cut point to apply, we applied an
ANOVA method to assess for any analyst, plate, and day differences
on either the untransformed or transformed data, depending on the
outcome of the Shapiro-Wilk’s test above. Analyst, plate, day, and
their interactions were set as fixed factors, whereas subject was
included as a random effect. Levene’s test for homogeneity of variance
was performed.29 A fixed screening cut point was indicated if there
were no differences or variances, whereas a floating cut point was re-
ported if there were differences between means only; otherwise a dy-
namic screening cut point was required.18 The correction factor was
calculated as the validation cut point minus the mean of the NC
values from the validation runs. The screening cut point was defined
as either the validation cut point or the mean of NC values from the
in-study run + correction factor, depending on whether the means
and variances between runs were similar.
The fixed specificity cut point was calculated using the method of
Shankar et al.18 For each sample, the percentage inhibition of signal









Data were assessed for outliers and normal distribution and treated
accordingly, as described above. For normally distributed data, the
fixed specificity cut point was calculated as mean % inhibition +
3.09  SD. For data not normalized by transformations, the speci-
ficity cut point was calculated as medium + 99% quantile. ANOVA
techniques were applied to assess for analyst, plate, and day
differences.
In the event of differences between analysts for either inhibited or un-
inhibited samples, the sensitivity analysis was performed separately
for each analyst. Each dilution curve was analyzed using a four-
parameter model. For a floating cut point, separate curves were
analyzed for each plate, whereas for a fixed cut point the data were
combined from all plates. The screening assay cut point determined
to be appropriate for the method was back-calculated onto the stan-
dard curve for each plate to obtain the log concentrations of the
screening cut points. These were averaged across all plates and a
95% confidence interval obtained for the overall mean on the log
scale. The back-transformed upper 95% confidence interval was
calculated, which was defined as the sensitivity of the assay.
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